Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.
Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.
Dr de Cogan said: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye.
“From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
“Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD.
“They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen, said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and clinical trials.
“We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy Path on April 17, 2019 at 7:53 am
Adverum announced that the FDA has placed a clinical hold on one of its gene therapy products known as ADVM-022 to treat patients with wet age-related macular degeneration. Responses for the FDA's ... […]
- A hidden footprint: embryological origins of age related macular degeneration on April 17, 2019 at 6:27 am
To address this, Sivapathasuntharam et al.  examined retinal development in Cfh−/− and Cfh+/− mice and showed significant disruptions at the retinal/RPE interface. However, after retinal ... […]
- FDA accepts Novartis’s BLA for brolucizumab for treatment of wet AMD on April 17, 2019 at 12:07 am
Novartis said that the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for brolucizumab (RTH258) as a potential treatment for wet age-related macular ... […]
- US FDA accepts Novartis' BLA for brolucizumab to treat wet age-related macular degeneration on April 16, 2019 at 8:30 pm
Novartis announced that the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular ... […]
- Novartis' BLA Acceptance Allows Entrance Into Large And Turbulent Wet AMD Market on April 16, 2019 at 8:24 pm
Novartis announced that the FDA had accepted its BLA for brolucizumab to treat patients with wet age-related macular degeneration. The company chose to use one of its priority review vouchers to ... […]
- FDA places clinical hold on IND application for Adverum’s wet AMD gene therapy on April 16, 2019 at 8:21 am
The FDA has placed a clinical hold on Adverum Biotechnologies’ investigational new drug application for its gene therapy candidate for wet age-related macular degeneration until it receives further ... […]
- Artificial intelligence project identifies existing drugs that have potential to treat AMD on April 16, 2019 at 6:59 am
The initial results from an artificial intelligence project show a number of existing drugs have the potential to reduce sight loss from age-related macular degeneration, the leading cause of sight ... […]
- Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval on April 16, 2019 at 6:54 am
Officials with the FDA have accepted Novartis’ Biologics License Application (BLA) for brolucizumab (RTH258), a humanized single-chain antibody fragment (scFv), for the treatment of wet age-related ... […]
- LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration on April 11, 2019 at 4:49 am
"I am delighted that we are able to offer some of our patients this very exciting new treatment," remarked Professor Ben Burton, Visiting Professor at the University of East Anglia, and ... […]
via Bing News